Design Therapeutics Reports $20.3M Third-Quarter Net Loss
Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, compared with a $17 million loss a year earlier. Diluted EPS was $(0.32).
Design Therapeutics reported a net loss of $20.3M for the third quarter of 2026, compared with a $17M loss in the prior-year quarter, as it continued advancing clinical programs for Friedreich ataxia, FECD and DM1.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Design Therapeutics, Inc…